Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05).

about

Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05).

Item

http://www.wikidata.org/entity/Q49330513

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Phase II study of rituximab gi ...... cancer research group (E1F05).

@en

Phase II study of rituximab gi ...... entral nervous system lymphoma

@nl

type

Item

label

Phase II study of rituximab gi ...... cancer research group (E1F05).

@en

Phase II study of rituximab gi ...... entral nervous system lymphoma

@nl

prefLabel

Phase II study of rituximab gi ...... cancer research group (E1F05).

@en

Phase II study of rituximab gi ...... entral nervous system lymphoma

@nl

P1476

Phase II study of rituximab gi ...... cancer research group (E1F05).

@en

P2093

Anne O'Neill

http://www.w3.org/2001/XMLSchema#string

David Schiff

http://www.w3.org/2001/XMLSchema#string

Dennis Moore

http://www.w3.org/2001/XMLSchema#string

Erin M Dunbar

http://www.w3.org/2001/XMLSchema#string

Lawrence R Kleinberg

http://www.w3.org/2001/XMLSchema#string

Lode J Swinnen

http://www.w3.org/2001/XMLSchema#string

Philip H Imus

http://www.w3.org/2001/XMLSchema#string

Ranjana H Advani

http://www.w3.org/2001/XMLSchema#string

Sachin Gujar

http://www.w3.org/2001/XMLSchema#string

Stuart A Grossman

http://www.w3.org/2001/XMLSchema#string

P2860

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.

Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome

High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma.

High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma

Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10.

Rituximab monotherapy for patients with recurrent primary CNS lymphoma.

R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.

Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI.

Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma.

Surgery for primary CNS lymphoma? Challenging a paradigm.

P304

766-773

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.22332

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29416652

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

5787508

http://www.w3.org/2001/XMLSchema#string